The study of the mechaniem of bronchial heperresponsiveness the effect of inflammatory cytokines on autononic receptors

作为一项临床研究，我们测定了支气管哮喘患者痰中嗜酸性粒细胞和嗜酸性阳离子蛋白（ECP）的数量，并将这些数据与支气管高反应性、肺功能及其症状进行了比较。我们在服用Th2细胞因子抑制剂tosilate suplatast （IPD）前后测量了相同的因子。我们还评估了辣椒素咳嗽阈值、咳嗽评分和治疗评分。结果支气管哮喘患者出现支气管高反应性增高、小气道病变及ECP浓度增高。支气管哮喘患者经IPD治疗后咳嗽明显减少，咳嗽阈值明显提高。这些结果发表在2002年3月21日至23日的日本过敏症学会会议上。并将在第97届ats会议（2002年5月19日至22日，美国亚特兰大）上发表。作为一项基础研究，我们利用正电子发射断层扫描（PET）对毒蕈碱受体的可视化进行了评价。11[C]3NMPB，毒蕈碱受体拮抗剂注入静脉，测定其体内代谢分布及肺放射性。11[C]3NMPB在双肺中均检测到高放射性，提示人体肺中存在丰富的毒蕈碱受体。这些结果的一部分将在第42届日本呼吸会议（2002年4月4日至6日，仙台）和第97届ATS会议（2002年5月19日至22日，美国亚特兰大）上发表。

As a clinical research, we measured the ntunber of eosinopils and eosinophil cationic protein (ECP) in the sputum of the patients with bronchial asthma and we compared these data with bronchial hyperresponsiveness, pulmonary functions and their symptoms. We measured the same factors before and after administration of suplatast tosilate (IPD), a Th2 cytokine inhibitor. We also evaluated capsaicin cough threshold, the cough scores and the therapeutic scores. _As results, increased bronchial hyperresponsiveness, small airway diseases and increased ECP concentrations were observed in the patients with bronchial asthma. After administration of IPD cough was decreased and couth threshold improved significantly in thepatients with bronchial asthma. These results were published at the Japanese Society of Allergology Meeting (March 21 to 23, 2002. Makuhari, Chiba, Japan), and will be published at the 97th-ATS meeting (May 19 to 22, 2002, Atlanta, USA).As a basic research, we evaluated the visualization of muscarinic receptors by using positron emission tomography (PET). 11[C]3NMPB, muscarinic receptor antagonist was administered into the vein and body metabolism and distribution were measured and radioactivity in the lungs was counted. Radioactivity of 11[C]3NMPB were detected highly in both lungs suggesting existence of abundant muscarinic receptors in human lung. The part of these results will be publishd at the 42nd Japanese Respiratory Meeting (April 4 to 6, 2002, Sendai) and at the 97th ATS meeting (May 19 to 22, 2002, Atlanta, USA).